CClinicalTrials.gg
CompletedNCT02025270Updated Mar 1, 2023

MSCs For Treatment of Azoospermic Patients

A Phase 1/2 interventional study of Stem Cells in Male Infertility, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to male participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Al-Azhar University · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2012, registered Dec 2013).
Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Study summary

In this study, we performed autologous BMDMSC transplantation to the testis of Azoospermic patients in a trial to enhance and activate the spermatogonial stem cells of the testis and aiming to produce motile sperm.

Read the detailed description

Bone marrow aspirated and stem cells were isolated, cultured and characterized using flow cytometer. Stem cells prepared according to GMP regulations then injected into rete testis using special syringe. Patients follow up will carried out for a year , three month interval. FSH, testosterone, testicular size as well as sexual potency will assessed every three months.

02

Conditions studied

  • Male Infertility

Keywords

  • Azoospermia, Spermatogonial Arrest, Maturation Arrest.
03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's planned enrollment of 100 is below the median of 120 across 1,698 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 505 studies on the registry; 167 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • All Non obstructive Azoospermic Patients.
  • Azoospermic Patients due to Administration of Chemo/Radiotherapy.

Exclusion criteria

Exclusion Criteria:

  • Patients with Testicular Cancer.
  • Patients with Complete Deletion of Chromosome Y AZF (a,b,c) Regions.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Laboratory and Clinical

    60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.

    Biological: Stem Cells

Interventions

  • BiologicalStem Cells

    60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.

    Also known as: Stem Cell Dose, 3-5 Million Autologous MSCs Injected into rete testis.

06

What researchers measure

Primary outcomes

  1. All Cases Improvement

    Hormonal Assessment: Serum (Testosterone , FSH, LH and Prolactin). Testicular Size. Sexual Potency.

    Time frame: One Year (12-Month)

Secondary outcomes

  1. All Cases Fertility Improvement

    Hormonal Assessment: Serum (Testosterone , FSH, LH and Prolactin) Testicular size and Sexual Potency.

    Time frame: One Year (12-Month)

07

Study locations

1 site
  • Al Azhar University , School of Medicine
    Cairo, 11884, Egypt
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02025270
Lead sponsor
Al-Azhar University
Collaborators
Cairo University
Responsible party
Sayed Bakry (Associate Professor , Consultant of Separation and Culturing of Stem Cells, Al-Azhar University) — Principal investigator
First posted
Jan 1, 2014
Start date
Oct 15, 2012
Primary completion
Oct 15, 2016
Completion
Dec 20, 2022
Last update
Mar 1, 2023

Study contacts

Taimour M Khalifa, MD Professor
principal investigator · Al-Azhar University
Sayed Bakry, PhD
study director · Al-Azhar University
Saad Moneer, MSc
study chair · Al-Azhar University
Ahmed Kadeh, MSc
study chair · Al-Azhar University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion